Concordia Healthcare was Downgraded to a Sell Rating at Canaccord Genuity

By Ryan Adsit

Concordia Healthcare (NASDAQ: CXRX) received a Sell rating and a $1 price target from Canaccord Genuity analyst Neil Maruoka on November 4. The company’s shares closed yesterday at $1.83, close to its 52-week low of $1.69.

According to TipRanks.com, Maruoka is ranked 0 out of 5 stars with an average return of -42.9% and a 12.5% success rate. Maruoka covers the Healthcare sector, focusing on stocks such as Merus Labs International, Cardiome Pharma Corp., and Oncolytics Biotech.

Concordia Healthcare has an analyst consensus of Moderate Sell.

The company has a one year high of $44 and a one year low of $1.69. Currently, Concordia Healthcare has an average volume of 2.22M.

Concordia International Corp. develops pharmaceutical products and medical devices. The company is an integrated, specialty healthcare company that focuses on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in Oakville, Canada.